Alumis Inc. (ALMS)

Compare

8.87

-0.97

(-9.81%)

As of 2:10:55 PM EDT. Market Open.

Alumis and Kaken sign agreement in Japan to develop ESK-001

Kaken will pay Alumis $40m in upfront and near-term co-development payments from 2025 to 2026.

Pharmaceutical Technology 9 days ago

ALMS
-9.81%
Sector Update: Health Care Stocks Steady Premarket Tuesday

Health care stocks were steady premarket Tuesday as the Health Care Select Sector SPDR Fund (XLV) sl

PREMIUM
MT Newswires 9 days ago

ALMS
-9.81%
Alumis, Kaken Pharmaceutical Enter Collaboration, Licensing Deal for Dermatology Drug

Alumis (ALMS) and Kaken Pharmaceutical have struck a collaboration and licensing agreement to develo

PREMIUM
MT Newswires 9 days ago

ALMS
-9.81%
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

- Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales -Deal underscores the commercial potential of Alumis’ ESK-001 and leverages Kaken’s regional capabilities and expertise in novel dermatology treatments -Kaken has the option to license ESK-001 for further clinical development and commercialization in rheumatological and gastrointest

GlobeNewswire 9 days ago

ALMS
-9.81%
Why Alumis Inc. (ALMS) Went Down On Thursday?

We recently published a list of Thursday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where Alumis Inc. (NASDAQ:ALMS) stands against other Thursday’s worst-performing stocks. Wall Street’s main indices edged lower on Thursday, erasing gains from the previous trading day that was buoyed by the Federal Reserve’s decision to […]

Insider Monkey 13 days ago

ALMS
-9.81%
^GSPC
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD program data readout now expected 1Q 2026 – – Presented Phase 1 clinical data at ACTRIMS 2025 demonstrating first-in-class oral TYK2 inhibitor A-005 has ability to cross blood-brain barrier and was well tolerated; Phase 2 in MS to begin 2H 2025 – – Announced merger agreement with ACE

GlobeNewswire 14 days ago

ALMS
-9.81%
Alumis to Present at Leerink's 2025 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at Leerink's 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 10:40

GlobeNewswire 24 days ago

ALMS
-9.81%
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupusPhase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90, PASI 100, and sPGA 0ESK-001 was generally well-tolerated at one year, with no new safety findingsData further support ESK-001’s potential to offer a highly differentiated and best-in-class treatment opti

GlobeNewswire 26 days ago

ALMS
-9.81%
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheetSOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN) (“ACELYRIN”) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of A

GlobeNewswire 30 days ago

ALMS
-9.81%
SLRN
-5.29%
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN) and Alumis Inc. (Nasdaq: ALMS) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, “Alumis an

GlobeNewswire 30 days ago

ALMS
-9.81%
SLRN
-5.29%
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, after due consideration in consultation with its independent financial and legal advisors, its Board of Directors determined that the unsolicited indication of interest from Con

GlobeNewswire 30 days ago

ALMS
-9.81%
SLRN
-5.29%
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – – Additional Phase 2 e-poster presentations to describe patient-reported outcomes, disease biomarker activity and pharmacokinetic data of ESK-001 in psoriasis patients – – Phase 3 ONWARD program topline data now expected in Q1 2026 – SOUTH SAN FRANCISCO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alum

GlobeNewswire last month

ALMS
-9.81%
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced the Company will give two data presentations on A-005, a potent, selective, central nervous system (CNS) penetrant tyrosine kinase 2 (TYK2) inhibitor, on Friday

GlobeNewswire last month

ALMS
-9.81%
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that repr

GlobeNewswire last month

SLRN
-5.29%
ALMS
-9.81%
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 a

GlobeNewswire last month

ALMS
-9.81%
Alumis and Acelyrin sign merger agreement

The funds will cover operating expenses and capital expenditure needs up to 2027.

Pharmaceutical Technology last month

ALMS
-9.81%
We're Keeping An Eye On Alumis' (NASDAQ:ALMS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. last month

ALMS
-9.81%
Immune drugmakers Alumis and Acelyrin to merge

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the new company with a bigger cash balance and three drugs in testing.

BioPharma Dive last month

ALMS
-9.81%
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN’s lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple cl

GlobeNewswire last month

ALMS
-9.81%
SLRN
-5.29%
Alumis Strengthens Leadership Team with Key Appointments

Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies at global biopharmaceutical companies Sara Klein promoted to Chief Legal Officer; leveraging deep expertise advising biopharmaceutical companies on legal matters across all stages of development and growth SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral

GlobeNewswire 2 months ago

ALMS
-9.81%

Performance Overview

Return	ALMS	S&P 500 (^GSPC)
YTD	+12.91%	-7.70%
1-Year	-34.26%	+4.17%
3-Year	-34.26%	+19.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Alumis Inc. (ALMS)

Alumis and Kaken sign agreement in Japan to develop ESK-001

Sector Update: Health Care Stocks Steady Premarket Tuesday

Alumis, Kaken Pharmaceutical Enter Collaboration, Licensing Deal for Dermatology Drug

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Why Alumis Inc. (ALMS) Went Down On Thursday?

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Alumis and Acelyrin sign merger agreement

We're Keeping An Eye On Alumis' (NASDAQ:ALMS) Cash Burn Rate

Immune drugmakers Alumis and Acelyrin to merge

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments

Performance Overview